Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Disruption of IRE1α through its kinase domain attenuates multiple myeloma.

Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. doi: 10.1073/pnas.1906999116. Epub 2019 Aug 1.

2.

Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members.

Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, Ultsch M, De Leon Boenig G, Harris SF, Leonard B, Scales SJ, Zhu JW, Christensen E, Hang JQ, Brezski RJ, Marsters S, Ashkenazi A, Sukumaran S, Chiu H, Cubas R, Kim JM, Lazar GA.

MAbs. 2019 Aug/Sep;11(6):996-1011. doi: 10.1080/19420862.2019.1625662. Epub 2019 Jun 20.

PMID:
31156033
3.

Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate.

Chang TK, Lawrence DA, Lu M, Tan J, Harnoss JM, Marsters SA, Liu P, Sandoval W, Martin SE, Ashkenazi A.

Mol Cell. 2018 Aug 16;71(4):629-636.e5. doi: 10.1016/j.molcel.2018.06.038.

4.

Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey.

Zuch de Zafra CL, Ashkenazi A, Darbonne WC, Cheu M, Totpal K, Ortega S, Flores H, Walker MD, Kabakoff B, Lum BL, Mounho-Zamora BJ, Marsters SA, Dybdal NO.

Cell Death Dis. 2016 Aug 11;7(8):e2338. doi: 10.1038/cddis.2016.241.

5.

Membrane display and functional analysis of juxtacrine ligand-receptor signaling.

Nair PM, Ngu H, Torres E, Marsters S, Lawrence DA, Stephan JP, Komuves L, Ashkenazi A.

Biotechniques. 2015 Oct 1;59(4):231-8, 240. doi: 10.2144/000114342. eCollection 2015 Oct.

6.

Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity.

Yin Y, Djakovic S, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve RM, Wu Y, Merchant M, Ashkenazi A, Carter PJ.

Mol Cancer Ther. 2015 Oct;14(10):2270-8. doi: 10.1158/1535-7163.MCT-14-1050. Epub 2015 Aug 12.

7.

MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.

Chen TT, Filvaroff E, Peng J, Marsters S, Jubb A, Koeppen H, Merchant M, Ashkenazi A.

EBioMedicine. 2015 Mar 28;2(5):406-20. doi: 10.1016/j.ebiom.2015.03.021. eCollection 2015 May.

8.

Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.

Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF, Ngu H, Sagolla M, Komuves L, Bourgon R, Settleman J, Ashkenazi A.

Proc Natl Acad Sci U S A. 2015 May 5;112(18):5679-84. doi: 10.1073/pnas.1418962112. Epub 2015 Apr 20.

9.

TRAF2 is a biologically important necroptosis suppressor.

Petersen SL, Chen TT, Lawrence DA, Marsters SA, Gonzalvez F, Ashkenazi A.

Cell Death Differ. 2015 Nov;22(11):1846-57. doi: 10.1038/cdd.2015.35. Epub 2015 Apr 17.

10.

Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis.

Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, Paton AW, Paton JC, Walter P, Ashkenazi A.

Science. 2014 Jul 4;345(6192):98-101. doi: 10.1126/science.1254312.

11.

E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis.

Lu M, Marsters S, Ye X, Luis E, Gonzalez L, Ashkenazi A.

Mol Cell. 2014 Jun 19;54(6):987-98. doi: 10.1016/j.molcel.2014.04.029. Epub 2014 May 29.

12.

Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.

Wilson NS, Duewell P, Yang B, Li Y, Marsters S, Koernig S, Latz E, Maraskovsky E, Morelli AB, Schnurr M, Ashkenazi A.

J Immunol. 2014 Apr 1;192(7):3259-68. doi: 10.4049/jimmunol.1302011. Epub 2014 Mar 7.

13.

TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer.

Gonzalvez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, Pham VC, Stephan JP, Lill J, Ashkenazi A.

Mol Cell. 2012 Dec 28;48(6):888-99. doi: 10.1016/j.molcel.2012.09.031. Epub 2012 Nov 8.

14.

Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, Pitti R, Marsters S, Weimer RM, Singh M, Ashkenazi A.

Cancer Cell. 2012 Jul 10;22(1):80-90. doi: 10.1016/j.ccr.2012.05.014.

15.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J.

Nat Med. 2012 Jan 22;18(2):221-3. doi: 10.1038/nm.2609. Erratum in: Nat Med. 2012 Sep;18(9):1445. Somasekar, Seshagiri [corrected to Seshagiri, Somasekar].

PMID:
22270724
16.

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J.

Sci Transl Med. 2011 Dec 14;3(113):113ra126. doi: 10.1126/scitranslmed.3002669.

17.

Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET.

Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S, Bodepudi S, Ashkenazi A.

J Biol Chem. 2011 Sep 16;286(37):32762-74. doi: 10.1074/jbc.M111.239384. Epub 2011 Jul 22.

18.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A.

Cancer Cell. 2011 Jan 18;19(1):101-13. doi: 10.1016/j.ccr.2010.11.012.

19.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A.

J Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017. Epub 2009 Apr 20.

20.

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A.

Cell Death Differ. 2008 Apr;15(4):751-61. doi: 10.1038/sj.cdd.4402306. Epub 2008 Jan 25.

21.

Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists.

Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS.

J Mol Biol. 2006 Aug 18;361(3):522-36. Epub 2006 Jul 7.

PMID:
16859704
22.

Engineering an APRIL-specific B cell maturation antigen.

Patel DR, Wallweber HJ, Yin J, Shriver SK, Marsters SA, Gordon NC, Starovasnik MA, Kelley RF.

J Biol Chem. 2004 Apr 16;279(16):16727-35. Epub 2004 Feb 4.

23.

TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice.

Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS.

Nat Immunol. 2001 Jul;2(7):632-7.

PMID:
11429548
24.

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.

Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ.

J Immunol. 2001 Apr 15;166(8):4891-8.

25.

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A.

Nat Med. 2001 Apr;7(4):383-5. No abstract available.

PMID:
11283636
26.

Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity.

Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM.

Nat Immunol. 2000 Jul;1(1):37-41.

PMID:
10881172
27.

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A.

Curr Biol. 2000 Jun 29;10(13):785-8.

28.

Control of apoptosis signaling by Apo2 ligand.

Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A.

Recent Prog Horm Res. 1999;54:225-34. Review.

PMID:
10548878
29.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.

J Clin Invest. 1999 Jul;104(2):155-62.

30.

Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2.

Chuntharapai A, Gibbs V, Lu J, Ow A, Marsters S, Ashkenazi A, De Vos A, Jin Kim K.

J Immunol. 1999 Jul 15;163(2):766-73.

31.

Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR.

Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, Gray AM, Dowd AD, Brush AD, Heldens AD, Schow AD, Goddard AD, Wood WI, Baker KP, Godowski PJ, Ashkenazi A.

Curr Biol. 1999 Feb 25;9(4):215-8.

32.

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A.

Nature. 1998 Dec 17;396(6712):699-703.

PMID:
9872321
33.

Identification of a ligand for the death-domain-containing receptor Apo3.

Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A.

Curr Biol. 1998 Apr 23;8(9):525-8.

34.

A novel receptor for Apo2L/TRAIL contains a truncated death domain.

Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A.

Curr Biol. 1997 Dec 1;7(12):1003-6.

35.

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A.

Science. 1997 Aug 8;277(5327):818-21.

37.

Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B.

Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A.

Curr Biol. 1996 Dec 1;6(12):1669-76.

38.

Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA.

Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A.

Curr Biol. 1996 Jun 1;6(6):750-2.

39.

Ligand-induced assembly and activation of the gamma interferon receptor in intact cells.

Bach EA, Tanner JW, Marsters S, Ashkenazi A, Aguet M, Shaw AS, Schreiber RD.

Mol Cell Biol. 1996 Jun;16(6):3214-21.

40.

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A.

J Biol Chem. 1996 May 31;271(22):12687-90.

41.

A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.

Chamow SM, Zhang D, Tan XY, Mhatre SM, Marsters SA, Peers DH, Byrn RA, Ashkenazi A, Junghans RP.

J Hematother. 1995 Oct;4(5):439-46.

PMID:
8581382
42.

Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain.

Marsters SA, Pennica D, Bach E, Schreiber RD, Ashkenazi A.

Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5401-5.

43.

Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.

Jin H, Yang R, Marsters S, Ashkenazi A, Bunting S, Marra MN, Scott RW, Baker JB.

J Clin Invest. 1995 Apr;95(4):1947-52.

44.

Molecular and biological properties of an interleukin-1 receptor immunoadhesin.

Pitti RM, Marsters SA, Haak-Frendscho M, Osaka GC, Mordenti J, Chamow SM, Ashkenazi A.

Mol Immunol. 1994 Dec;31(17):1345-51.

PMID:
7997246
45.

Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage.

Beck JT, Marsters SA, Harris RJ, Carter P, Ashkenazi A, Chamow SM.

Mol Immunol. 1994 Dec;31(17):1335-44.

PMID:
7997245
46.

Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody.

Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A.

J Infect Dis. 1994 Nov;170(5):1323-6.

PMID:
7963738
47.

A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.

Chamow SM, Zhang DZ, Tan XY, Mhatre SM, Marsters SA, Peers DH, Byrn RA, Ashkenazi A, Junghans RP.

J Immunol. 1994 Nov 1;153(9):4268-80.

PMID:
7930627
48.
49.

Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.

Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A.

J Immunol. 1994 Feb 1;152(3):1347-53.

PMID:
8301136
50.

Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin.

Haak-Frendscho M, Marsters SA, Chamow SM, Peers DH, Simpson NJ, Ashkenazi A.

Immunology. 1993 Aug;79(4):594-9.

Supplemental Content

Loading ...
Support Center